Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Simultaneous Assessment in vitro of Transporter and Metabolic Processes in Hepatic Drug Clearance: Use of a media loss approach.

Harrison J, De Bruyn T, Darwich AS, Houston JB.

Drug Metab Dispos. 2018 Feb 8. pii: dmd.117.079590. doi: 10.1124/dmd.117.079590. [Epub ahead of print]

PMID:
29439129
2.

Implications of inter-correlation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide.

Doki K, Darwich AS, Achour B, Tornio A, Backman JT, Rostami-Hodjegan A.

Br J Clin Pharmacol. 2018 Jan 30. doi: 10.1111/bcp.13533. [Epub ahead of print]

PMID:
29381228
3.

Virtual bioequivalence for achlorhydric subjects: The use of PBPK modelling to assess the formulation-dependent effect of achlorhydria.

Doki K, Darwich AS, Patel N, Rostami-Hodjegan A.

Eur J Pharm Sci. 2017 Nov 15;109:111-120. doi: 10.1016/j.ejps.2017.07.035. Epub 2017 Aug 1.

4.

Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future.

Darwich AS, Ogungbenro K, Vinks AA, Powell JR, Reny JL, Marsousi N, Daali Y, Fairman D, Cook J, Lesko LJ, McCune JS, Knibbe C, de Wildt SN, Leeder JS, Neely M, Zuppa AF, Vicini P, Aarons L, Johnson TN, Boiani J, Rostami-Hodjegan A.

Clin Pharmacol Ther. 2017 May;101(5):646-656. doi: 10.1002/cpt.659. Epub 2017 Apr 4. Review.

PMID:
28182269
5.

IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results.

Margolskee A, Darwich AS, Pepin X, Aarons L, Galetin A, Rostami-Hodjegan A, Carlert S, Hammarberg M, Hilgendorf C, Johansson P, Karlsson E, Murphy D, Tannergren C, Thörn H, Yasin M, Mazuir F, Nicolas O, Ramusovic S, Xu C, Pathak SM, Korjamo T, Laru J, Malkki J, Pappinen S, Tuunainen J, Dressman J, Hansmann S, Kostewicz E, He H, Heimbach T, Wu F, Hoft C, Laplanche L, Pang Y, Bolger MB, Huehn E, Lukacova V, Mullin JM, Szeto KX, Costales C, Lin J, McAllister M, Modi S, Rotter C, Varma M, Wong M, Mitra A, Bevernage J, Biewenga J, Van Peer A, Lloyd R, Shardlow C, Langguth P, Mishenzon I, Nguyen MA, Brown J, Lennernäs H, Abrahamsson B.

Eur J Pharm Sci. 2017 Jan 1;96:610-625. doi: 10.1016/j.ejps.2016.10.036. Epub 2016 Nov 2.

PMID:
27816631
6.

IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes.

Darwich AS, Margolskee A, Pepin X, Aarons L, Galetin A, Rostami-Hodjegan A, Carlert S, Hammarberg M, Hilgendorf C, Johansson P, Karlsson E, Murphy D, Tannergren C, Thörn H, Yasin M, Mazuir F, Nicolas O, Ramusovic S, Xu C, Pathak SM, Korjamo T, Laru J, Malkki J, Pappinen S, Tuunainen J, Dressman J, Hansmann S, Kostewicz E, He H, Heimbach T, Wu F, Hoft C, Pang Y, Bolger MB, Huehn E, Lukacova V, Mullin JM, Szeto KX, Costales C, Lin J, McAllister M, Modi S, Rotter C, Varma M, Wong M, Mitra A, Bevernage J, Biewenga J, Van Peer A, Lloyd R, Shardlow C, Langguth P, Mishenzon I, Nguyen MA, Brown J, Lennernäs H, Abrahamsson B.

Eur J Pharm Sci. 2017 Jan 1;96:626-642. doi: 10.1016/j.ejps.2016.09.037. Epub 2016 Sep 28.

PMID:
27693299
7.

IMI - oral biopharmaceutics tools project - evaluation of bottom-up PBPK prediction success part 1: Characterisation of the OrBiTo database of compounds.

Margolskee A, Darwich AS, Pepin X, Pathak SM, Bolger MB, Aarons L, Rostami-Hodjegan A, Angstenberger J, Graf F, Laplanche L, Müller T, Carlert S, Daga P, Murphy D, Tannergren C, Yasin M, Greschat-Schade S, Mück W, Muenster U, van der Mey D, Frank KJ, Lloyd R, Adriaenssen L, Bevernage J, De Zwart L, Swerts D, Tistaert C, Van Den Bergh A, Van Peer A, Beato S, Nguyen-Trung AT, Bennett J, McAllister M, Wong M, Zane P, Ollier C, Vicat P, Kolhmann M, Marker A, Brun P, Mazuir F, Beilles S, Venczel M, Boulenc X, Loos P, Lennernäs H, Abrahamsson B.

Eur J Pharm Sci. 2017 Jan 1;96:598-609. doi: 10.1016/j.ejps.2016.09.027. Epub 2016 Sep 23.

PMID:
27671970
8.

Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1-OH-midazolam in morbidly obese and weight loss surgery patients.

Brill MJ, Välitalo PA, Darwich AS, van Ramshorst B, van Dongen HP, Rostami-Hodjegan A, Danhof M, Knibbe CA.

CPT Pharmacometrics Syst Pharmacol. 2016 Jan;5(1):20-30. doi: 10.1002/psp4.12048. Epub 2015 Dec 18.

9.

Deconvolution and IVIVC: Exploring the Role of Rate-Limiting Conditions.

Margolskee A, Darwich AS, Galetin A, Rostami-Hodjegan A, Aarons L.

AAPS J. 2016 Mar;18(2):321-32. doi: 10.1208/s12248-015-9849-y. Epub 2015 Dec 14.

10.

The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients Before and One Year After Bariatric Surgery.

Brill MJ, van Rongen A, van Dongen EP, van Ramshorst B, Hazebroek EJ, Darwich AS, Rostami-Hodjegan A, Knibbe CA.

Pharm Res. 2015 Dec;32(12):3927-36. doi: 10.1007/s11095-015-1752-9. Epub 2015 Jul 23.

11.

Drug disposition and modelling before and after gastric bypass: immediate and controlled-release metoprolol formulations.

Gesquiere I, Darwich AS, Van der Schueren B, de Hoon J, Lannoo M, Matthys C, Rostami A, Foulon V, Augustijns P.

Br J Clin Pharmacol. 2015 Nov;80(5):1021-30. doi: 10.1111/bcp.12666. Epub 2015 Jul 6.

12.

Analysis of the impact of controlled release formulations on oral drug absorption, gut wall metabolism and relative bioavailability of CYP3A substrates using a physiologically-based pharmacokinetic model.

Olivares-Morales A, Kamiyama Y, Darwich AS, Aarons L, Rostami-Hodjegan A.

Eur J Pharm Sci. 2015 Jan 25;67:32-44. doi: 10.1016/j.ejps.2014.10.018. Epub 2014 Nov 5.

13.

Meta-analysis of the turnover of intestinal epithelia in preclinical animal species and humans.

Darwich AS, Aslam U, Ashcroft DM, Rostami-Hodjegan A.

Drug Metab Dispos. 2014 Dec;42(12):2016-22. doi: 10.1124/dmd.114.058404. Epub 2014 Sep 18.

14.

Evaluation of an In Silico PBPK Post-Bariatric Surgery Model through Simulating Oral Drug Bioavailability of Atorvastatin and Cyclosporine.

Darwich AS, Pade D, Rowland-Yeo K, Jamei M, Asberg A, Christensen H, Ashcroft DM, Rostami-Hodjegan A.

CPT Pharmacometrics Syst Pharmacol. 2013 Jun 12;2:e47. doi: 10.1038/psp.2013.23.

15.

A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution.

Darwich AS, Pade D, Ammori BJ, Jamei M, Ashcroft DM, Rostami-Hodjegan A.

J Pharm Pharmacol. 2012 Jul;64(7):1008-24. doi: 10.1111/j.2042-7158.2012.01538.x.

PMID:
22686346
16.

Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes.

Darwich AS, Henderson K, Burgin A, Ward N, Whittam J, Ammori BJ, Ashcroft DM, Rostami-Hodjegan A.

Br J Clin Pharmacol. 2012 Nov;74(5):774-87. doi: 10.1111/j.1365-2125.2012.04284.x. Review.

Supplemental Content

Loading ...
Support Center